Results 51 to 60 of about 9,316,170 (262)

Understanding progression in primary progressive multiple sclerosis: a longitudinal clinical and magnetic resonance imaging study [PDF]

, 2010
The work in this thesis applies magnetization transfer imaging (MTI) and conventional MRI measures (brain volume, T2 lesion load and enhancing lesions) to investigate the mechanisms underlying progression in primary progressive multiple sclerosis ...
Khaleeli, Z.
core  

Predicting the On-Study Relapse Rate for Multiple Sclerosis Patients in Clinical Trials [PDF]

, 2005
Background: The annual relapse rate has been commonly used as a primary efficacy endpoint in phase III multiple sclerosis (MS) clinical trials. The aim of this study was to determine the relative contribution of different possible prognostic factors ...
Chang, C., Polman, Chris, Kappos, L., Polman, C., Held, U., Heigenhauser, L., Shang, C., Heigenhauser, Ludwig, Kappos, Ludwig   +8 more
core   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Diagnosis and Management of Progressive Multiple Sclerosis

Biomedicines, 2019
Multiple sclerosis is a chronic autoimmune disease of the central nervous system that results in varying degrees of disability. Progressive multiple sclerosis, characterized by a steady increase in neurological disability independently of relapses, can ...
Gabrielle Macaron, Daniel Ontaneda
doaj   +1 more source

Comparing the Effect of Semi‐Immersive Virtual Reality, Computerized Cognitive Training, and Traditional Rehabilitation on Cognitive Function in Multiple Sclerosis: A Randomized Clinical Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Cognitive impairment is a common non‐motor symptom in Multiple Sclerosis (MS), negatively affecting autonomy and Quality of Life (QoL). Innovative rehabilitation strategies, such as semi‐immersive virtual reality (VR) and computerized cognitive training (CCT), may offer advantages over traditional cognitive rehabilitation (TCR ...
Maria Grazia Maggio, Desiree Latella, Lilla Bonanno, Paulo Cezar Rocha dos Santos, Marcos Maldonado‐Díaz, Meir Plotnik, Rosaria De Luca, Angelo Quartarone, Rocco Salvatore Calabrò   +8 more
wiley   +1 more source

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland [PDF]

, 2018
Background: Recent studies emphasise the importance of timely diagnosis and early initiation of disease-modifying treatment in the long-term prognosis of multiple sclerosis.
Calabrese, Pasquale, Rodgers, S., Kaufmann, Marco; https://orcid.org/, Kuhle, J., Puhan, M.A., Puhan, Milo A, Kuhle, Jens, Puhan, M. A., Kamm, Christian P, Kesselring, Jürg, Rodgers, Stephanie, Pot, Caroline, Steinemann, Nina, von Wyl, Viktor, Kamm, C.P., von Wyl, V., Salmen, A., Pot, C., Salmen, Anke, Steinemann, N., Kaufmann, M., Chan, A., Kamm, Christian Philipp, Chan, Andrew, Gobbi, C., Gobbi, Claudio, Kesselring, J., Calabrese, P.   +27 more
core   +2 more sources

White Matter Hyperintensity Burden and Short‐Interval Change Associated With Sleep Apnoea in the UK Biobank

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Purpose White matter hyperintensities (WMH) are a core neuroimaging marker of cerebral small vessel disease (CSVD). Sleep apnoea (SA) is a recognized vascular risk factor, but its associations with regional WMH burden, short‐interval WMH change and cognitive performance in population‐based cohorts remain incompletely defined. We
Peng Cheng, Diego Z. Carvalho, Shahid Karim, Anwar Chahal, Virend K. Somers   +4 more
wiley   +1 more source

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology
Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53 ...
Taylor R. Wicks, Anna Wolska, Diala Ghazal, Dejan Jakimovski, Bianca Weinstock‐Guttman, Alexander Burnham, Niels Bergsland, Michael G. Dwyer, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +10 more
doaj   +1 more source

Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
Background Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses.
Sarah L Minden, R Philip Kinkel, Helene T Machado, Jonathan S Levin, Meredith B Rosenthal, Lisa I Iezzoni   +5 more
doaj   +1 more source

Ocrelizumab in treatment of primary-progressive multiple sclerosis: systematic review

Качественная клиническая практика, 2018
Aim. To analyze the efficacy, safety and pharmacoeconomic indicators of ocrelizumab in adult patients with primary progressive multiple sclerosis (PPMS). Methods.
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, E. M. Olyushina, K. I. Polyakova, A. G. Fisun, M. G. Grinin, K. A. Kokushkin   +8 more
doaj   +1 more source